Linksbridge Pharma: this week's highlights
Each week, our team covers industry and R&D developments important to global health. From early-stage vaccines to multistakeholder initiatives supporting market health, we tell you what’s happening and why it matters. To access full coverage, sign up today.
Bavarian to up mpox shot production, transfer tech
Bavarian Nordic last week pledged to ramp up production of its mpox vaccine to ensure “continued equitable access.”
Responding to vaccine supply concerns in the wake of WHO and Africa CDC declarations of mpox public health emergencies, the Denmark-based company said it could supply up to 2 million doses this year and manufacture up to 10 million doses by the end of 2025.
The company also said it’s “working closely” with Africa CDC to expand mpox vaccine production capacity in Africa through technology transfers to “selected African manufacturers.”
In other supply news, Japan has pledged to send 3.5 million doses of KM Biologics’ LC16 vaccine to the DRC, according to DW. The country reportedly requested that the doses be used “specifically for children.” Both Bavarian Nordic’s Jynneos and LC16 are recommended by WHO, but KM Biologics’ shot is the only mpox jab currently approved for children, according to Reuters.
WHO PQs antimalarial from Nigeria’s Swipha
Swiss Pharma Nigeria Limited (Swipha) has become the first Nigerian manufacturer to notch WHO prequalification for key antimalarial drug sulfadoxine-pyrimethamine.
领英推荐
A joint announcement Wednesday from the company, Medicines for Malaria Venture and Unitaid said another Nigeria-based manufacturer?is expected to receive prequalification for the antimalarial soon.
Ervebo “highly protective” in real-world study
Merck’s Ebola shot was 84% effective against infection in the DRC during the country’s 2018-2020 Ebola outbreak, according to what authors called “the first” real-world study of the vaccine’s effectiveness, published Tuesday in The Lancet Infectious Diseases.
In this retrospective analysis assessing the most widespread use of Ervebo (rVSV-ZEBOV) to date, the jab was “highly protective” against disease and showed “robust” effectiveness under alternative definitions of possible Ebola virus disease exposure. The findings bolster evidence for vaccinating people at risk of Ebola exposure “as early as possible” to control outbreaks, “even in challenging settings,” per the authors.
Additional stories from our August 21 issue:
For full coverage of pharma, vaccines, AMR, and health campaign news, sign up for Linksbridge newsletters today.
MBBS Doctor from services institute of medical sciences
6 个月?? Stay Informed! ?? The 2024 Monkeypox outbreak is making headlines, and it's crucial to stay informed about this re-emerging viral threat. In our latest video, we break down everything you need to know about the Monkeypox virus, including its transmission, symptoms, and prevention measures. Whether you're concerned about the global spread or just want to be prepared, this comprehensive overview will give you the knowledge you need to protect yourself and your loved ones. ?? Watch the full video here: https://youtu.be/dzn5bP5LV04 ?? Don't forget to subscribe to our channel for more updates on global health issues and medical insights. Stay safe and informed, Fellow Medics! #Monkeypox2024 #PublicHealth #ViralOutbreak #StayInformed #HealthAwareness #FellowMedics This should help you effectively engage your audience and provide valuable information on the Monkeypox outbreak!